CN Patent

CN120271565A — Egfr突变形式的抑制剂

Assigned to Cable Chart Pharmaceutical Co · Expires 2025-07-08 · 1y expired

What this patent protects

本公开涉及EGFR突变形式的抑制剂。具体地，本公开提供由结构式(I)表示的化合物或其药学上可接受的盐，其可用于治疗癌症。

USPTO Abstract

本公开涉及EGFR突变形式的抑制剂。具体地，本公开提供由结构式(I)表示的化合物或其药学上可接受的盐，其可用于治疗癌症。

Drugs covered by this patent

Komzifti (ZIFTOMENIB) · Kura

Patent Metadata

Patent number: CN120271565A
Jurisdiction: CN
Classification: —
Expires: 2025-07-08
Drug substance claim: No
Drug product claim: No
Assignee: Cable Chart Pharmaceutical Co
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.